Skip to content
OpenCapital
Get started

NewAmsterdam Pharma Company NAMS EBITDA

EBITDA at other companies

Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-$134.51M+6.1%
Merck & Co. logo
Merck & Co.MRK
——
Amgen logo
AmgenAMGN
——
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
——
Eli Lilly logo
Eli LillyLLY
——

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Calculated from NewAmsterdam Pharma Company’s reported figures.

−$58.4Mebit+
$62.0KDepreciation Depletion & Amortization
=-$58.36M

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's EBITDA?
NewAmsterdam Pharma Company (NAMS) reported EBITDA of -$58.36M in Q1 2026.
How has NewAmsterdam Pharma Company's EBITDA changed year-over-year?
NewAmsterdam Pharma Company's EBITDA increased by 15.3% year-over-year, from -$68.87M to -$58.36M.
What is the long-term trend for NewAmsterdam Pharma Company's EBITDA?
Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's EBITDA has grown at a 59.3% compound annual growth rate (CAGR), from -$34.97M to -$225.46M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.